We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

OPRA:NASDAQOpera Limited Analysis

Data as of 2026-09-01 - not real-time

$19.23

Latest Price

9/10Risk

Risk Level: High

Executive Summary

Opera Limited is priced at $19.23 and its moving averages line up in bullish order, the shorter sitting above the longer. RSI sits at 49.0, which reads as neutral, and MACD momentum is bearish. The recent range runs from support at $17.63 up to resistance at $20.78.
On valuation the read is undervalued — earnings multiple of 13.9 versus a 16.1 sector average, below the peer group. Analyst price targets sit 36.7% above the current price. Revenue is growing at 24.6% on a 18.5% profit margin. The 4.07% dividend yield looks covered by current payout levels.
Risk scores 9 out of 10, which is high for this asset class. With 30-day volatility of 42.2%, a beta of 1.61 and a maximum drawdown of 42.9%, position sizing matters more than entry timing here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
Across every horizon the signals point the same way: buy, at a conviction of 7 out of 10.

Top Market Events

Opera Limited recently reported that it reached 288 million monthly active users in the first quarter of 2026, achieved...Opera to Announce Second Quarter 2026 Financial Results on August 25, 2026 PR Newswire OSLO, Norway, Aug.Opera Limited NASDAQ: OPRA , a leading global browser and AI agent company, today announced the appearance of Frode...

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 5/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • Trading above the 200-day average of 16.19
  • MACD momentum is negative

Medium Term

1–3 years
Positive
Model confidence: 6/10

Key Factors

  • Short-term moving averages stacked above long-term ones
  • P/E of 13.9 versus sector average of 16.1
  • Trading above the 200-day average of 16.19

Long Term

> 3 years
Positive
Model confidence: 7/10

Key Factors

  • P/E of 13.9 versus sector average of 16.1
  • Analyst targets imply +36.7% versus the current price
  • Profit margin of 18.5% is healthy

Key Metrics & Analysis

Financial Health

Revenue Growth24.60%
Profit Margin18.55%
P/E Ratio13.9
ROE12.86%
ROA6.22%
Debt/Equity0.79
P/B Ratio1.7
Op. Cash Flow$133.0M
Free Cash Flow$111.7M
Industry P/E16.1

Technical Analysis

TrendBullish
RSI49.0
Support$17.63
Resistance$20.78
MA 20$19.53
MA 50$19.34
MA 200$16.19
MACDBearish
VolumeIncreasing
Fear & Greed Index94.79

Valuation

Fair Value$44.50
Target Price$26.29
Upside/Downside36.69%
GradeUndervalued
TypeBlend
Dividend Yield4.07%

Risk Assessment

Beta1.61
Volatility42.21%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.